Echocardiographic Phenotype for Refined Risk Stratification and Treatment Selection in Light Chain Amyloidosis with Heart Failure

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Apr 21

PMID 37084113

Authors

Hong Yang

Rui Li

Fei Ma

Yujian Liu

Xingwei He

Qiao Yang

Dao Wen Wang

Hesong Zeng

Hong Wang

Affiliations

Soon will be listed here.

Abstract

Aims: Light chain amyloidosis (AL) patients with heart failure (HF) are usually with revised Mayo (rMayo) stage III/IV disease and have a poor prognosis. We sought to investigate whether and what echocardiographic phenotype provides value for further risk stratification and guiding optimal risk-adapted treatment in this subgroup of AL patients.

Methods And Results: 95 AL patients who presented with HF and were on rMayo stage III/IV were retrospectively included. Of them, 51 patients (53.7%) were with stage III, 44 (46.3%) were with stage IV, and 44 (46.3%) underwent chemotherapy. Laboratory and echocardiographic measurements were acquired before the initiation of chemotherapy. The relevance of different variables with survival was assessed in the entire cohort, chemotherapy, and non-chemotherapy group. By Multivariate Cox regression analysis, right ventricular wall thickness (RVT) [HR 1.145, 95% confidence interval (CI) 1.026-1.279, P = 0.016], relative wall thickness (RWT) (HR 6.709, 95% CI 1.101-40.877, P = 0.039), and left ventricular ejection fraction (LVEF) < 50% (HR 1.939, 95% CI 1.048-3.590, P = 0.035) were found to be independently associated with survival in the entire cohort, RWT (HR 15.488, 95% CI 2.045-117.292, P = 0.008) in the non-chemotherapy group, and RVT (HR 1.331, 95% CI 1.054-1.681, P = 0.016) in the chemotherapy group, respectively. Kaplan-Meier survival analysis revealed that survival was significantly reduced in the presence of RVT ≥ 6.5 mm or LVEF < 50% in the entire cohort, and the significance of RVT ≥ 6.5 mm was irrespective of rMayo stages. In the chemotherapy group, survival was decreased if RVT ≥ 6.5 mm alone or together with RWT ≥ 0.67 were present, particularly in patients on rMayo stage IV.

Conclusions: Echocardiographic phenotype provides incremental value beyond rMayo staging for predicting survival and could further guide treatment in advanced AL with HF. Those with high-risk echocardiographic phenotypes as higher RVT and RWT and lower LVEF had a worse prognosis.

References

Abdallah N, Dispenzieri A, Muchtar E, Buadi F, Kapoor P, Lacy M . Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv. 2021; 5(4):1029-1036. PMC: 7903228. DOI: 10.1182/bloodadvances.2020003782. View

Badano L, Kolias T, Muraru D, Abraham T, Aurigemma G, Edvardsen T . Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018; 19(6):591-600. DOI: 10.1093/ehjci/jey042. View

Barros-Gomes S, Williams B, Nhola L, Grogan M, Maalouf J, Dispenzieri A . Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC Cardiovasc Imaging. 2016; 10(4):398-407. DOI: 10.1016/j.jcmg.2016.04.008. View

Basset M, Milani P, Foli A, Nuvolone M, Benvenuti P, Nanci M . Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. Blood. 2022; 140(18):1964-1971. DOI: 10.1182/blood.2022016348. View

Bhole M, Sadler R, Ramasamy K . Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014; 51(Pt 5):528-42. DOI: 10.1177/0004563213518758. View

Cappelli F, Porciani M, Bergesio F, Perlini S, Attana P, Moggi Pignone A . Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2011; 13(5):416-22. DOI: 10.1093/ejechocard/jer289. View

Cohen O, Ismael A, Pawarova B, Manwani R, Ravichandran S, Law S . Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. Eur Heart J. 2021; 43(4):333-341. DOI: 10.1093/eurheartj/ehab507. View

Comenzo R, Vosburgh E, Simms R, Bergethon P, Sarnacki D, Finn K . Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996; 88(7):2801-6. View

DePace N, Colby J, Hakki A, Manno B, Horowitz L, Iskandrian A . Poor R wave progression in the precordial leads: clinical implications for the diagnosis of myocardial infarction. J Am Coll Cardiol. 1983; 2(6):1073-9. DOI: 10.1016/s0735-1097(83)80332-5. View

10.

Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T . Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22(18):3751-7. DOI: 10.1200/JCO.2004.03.029. View

11.

Falk R, Skinner M . The systemic amyloidoses: an overview. Adv Intern Med. 2000; 45:107-37. View

12.

Falk R, Alexander K, Liao R, Dorbala S . AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12):1323-41. DOI: 10.1016/j.jacc.2016.06.053. View

13.

Gertz M, Lacy M, Dispenzieri A, Kumar S, Dingli D, Leung N . Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2012; 48(4):557-61. DOI: 10.1038/bmt.2012.170. View

14.

Gertz M . Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022; 97(6):818-829. DOI: 10.1002/ajh.26569. View

15.

Gottdiener J, Bednarz J, Devereux R, Gardin J, Klein A, Manning W . American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr. 2004; 17(10):1086-119. DOI: 10.1016/j.echo.2004.07.013. View

16.

Hwang I, Koh Y, Park J, Yoon Y, Kim H, Kim H . Time trajectory of cardiac function and its relation with survival in patients with light-chain cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2020; 22(4):459-469. DOI: 10.1093/ehjci/jeaa146. View

17.

Jaccard A, Comenzo R, Hari P, Hawkins P, Roussel M, Morel P . Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014; 99(9):1479-85. PMC: 4562537. DOI: 10.3324/haematol.2014.104109. View

18.

Kaufman G, Schrier S, Lafayette R, Arai S, Witteles R, Liedtke M . Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017; 130(7):900-902. DOI: 10.1182/blood-2017-01-763599. View

19.

Knight D, Zumbo G, Barcella W, Steeden J, Muthurangu V, Martinez-Naharro A . Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. JACC Cardiovasc Imaging. 2018; 12(5):823-833. DOI: 10.1016/j.jcmg.2018.02.016. View

20.

Kristensen S, Jhund P, Mogensen U, Rorth R, Abraham W, Desai A . Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017; 10(10). DOI: 10.1161/CIRCHEARTFAILURE.117.004409. View